Case Study: MiRXES achieves a successful US$1bn-plus HKEx IPO with Mewburn Ellis IP due diligence and FTO support

MiRXES achieves US$1bn-plus public listing with Mewburn Ellis

MiRXES, a Singapore-headquartered biotechnology company specializing in RNA-based diagnostic tests, faced the complex intellectual property challenges associated with preparing for its public listing on the Hong Kong Stock Exchange. The company engaged the vendor, Mewburn Ellis, to manage the full IP workstream required for the IPO.

Mewburn Ellis delivered a comprehensive solution, conducting full IP due diligence, extensive freedom-to-operate analysis, and a detailed review of MiRXES's patent estate and licensing arrangements. This work was successfully included in the listing prospectus, enabling MiRXES to achieve its US$1 billion-plus IPO. This milestone marked the company as the first Southeast Asian biotech firm to reach that valuation through a public listing.

MiRXES